Skip to content

Telemonitoring of uncontrolled hypertension

TELEHYPE: a trial of TELEmonitoring and self-management support of patients with uncontrolled HYPErtension

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN10969896
Enrollment
400
Registered
2019-07-01
Start date
2014-04-07
Completion date
Unknown
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hypertension, with a systolic blood pressure > 140 mmHg Circulatory System Essential (primary) hypertension

Interventions

Patients will be randomised to either: 1. Telemonitoring and internet-based self-management support for hypertension (TISH) focused on home blood pressure, co-morbidities and cardiovas

Sponsors

Leiden University Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with hypertension, with a systolic blood pressure > 140 mmHg 2. Patients who are willing to measure their blood pressure at home before and during 12 months of treatment 3. Access to the internet at home and ability to use it

Exclusion criteria

Exclusion criteria: 1. Serious psychological problems that may interfere with compliance or reliability of the measurements 2. Relevant somatic or psychiatric co-morbidity that interferes with the study 3. Systolic blood pressure >200 mmHg 4. Progressive signs of organ damage 5. Already using a home blood pressure device 6. Unable to understand the Dutch interface of PatientCoach

Design outcomes

Primary

MeasureTime frame
The proportion of patients with controlled OBP (i.e., <140/90 mm Hg or <130/80 mm Hg if diabetes or chronic kidney disease is present) at 6 and 12 months

Secondary

MeasureTime frame
1. Self-management skills and health education impact are measured by the Health Education Impact Questionnaire at baseline and 12 months 2. Motivation/user acceptance are measured by the Technology Acceptance Questionnaire at baseline, 4 and 12 months 3. Patient utilities are measured by the EQ-5D-3L at baseline, 4 and 12 months 4. Therapy adherence is measured by the Medication Adherence Rating Scale (MARS)) at baseline, 4 and 12 months

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026